By Fineline Cube 
German pharmaceutical giant Boehringer Ingelheim has released the latest results from the Beamion LUNG-1 trial, a Phase Ib study assessing the efficacy of its investigational HER2-targeted tyrosine kinase inhibitor (TKI) zongertinib in previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
Trial Results and Efficacy
Initial results in patients with advanced NSCLC with HER2 mutations in the TKD domain, who were previously treated with both platinum-based chemotherapy and subsequent HER2-directed antibody drug conjugates (ADC) (N=31), demonstrated an objective response rate (ORR) of 48% (95% CI: 32-65) with 97% (95% CI: 15-52) of patients achieving disease control. An exploratory cohort (n=20) that included previously treated patients with advanced NSCLC with HER2 mutations outside of the TKD demonstrated an investigator-assessed ORR of 30% (95% CI: 15-52) and a disease control rate (DCR) of 65% (95% CI: 43-82). This represents the largest known dataset of patients with previously treated advanced NSCLC who have HER2 mutations outside the TKD.-Fineline Info & Tech